Curtin University-led researchers have identified a novel approach to boost the absorption rate of medical cannabis when taken orally, which might be used to treat neurological illnesses such as Alzheimer’s disease, multiple sclerosis, and traumatic brain injuries in the future. Published in the journal PLOS ONE and supported by industry accomplice Zelira Therapeutics, the scientists had the option to make small capsules containing cannabinoids which, when taken orally, were consumed by the body quicker and entered the brain quickly in mice models suffering from neurological diseases, than when it was delivered in liquid form. Read on to know more about how CBD Capsules help in alleviating the symptoms of neurological disorders.
CBD Capsules For Neurological Disorders
Lead Researcher, Associate Professor Ryu Takechi from the Curtin Health Innovation Research Institute (CHIRI) and the School of Population Health at Curtin University, said there has been a developing interest in the utilization of cannabidiol to treat different neurological infections, however, there are limits due to its poor absorption and aversion to light and stomach acid when consumed orally.
“Cannabidiol is found in medicinal cannabis and is a popular natural remedy for people living with neurological and metabolic diseases. Due to limitations in absorption, we aimed to design and test a new drug delivery method,” Associate Professor Takechi said.
“Our team was able to significantly improve the absorption and brain delivery of cannabidiol by administering it in a novel microcapsule form, in combination with a naturally occurring bile acid.
“With this new capsulated structure, we had the option to further boost the brain delivery of cannabidiol by 40 times in animal models and we were additionally ready to shield the medication from oxidation and degradation by light, which help extend the shelf life of the product.
Findings Of The Study
Academic administrator Takechi said the findings might be useful in supporting the clinical use of CBD Capsules for neurological disorders such as Alzheimer’s, Multiple Sclerosis, and many more.
“In this study, we were able to show for the first time that a bile acid actually increased the uptake and retention of cannabidiol within the brain. This shows that bile acids, could be used to enhance the delivery of cannabidiol when taken orally, particularly when treating neurological disorders,” Associate Professor Takechi said.
“Further research is needed to test whether this type of drug delivery method could be successful in human studies, but our findings are very promising.” Dr. Oludare Odumosu, CEO of Zelira, expressed his joy with the outcome of the partnership with Associate Professor Takechi and his colleagues.